Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer

SABCS 2012

Published: 12 Dec 2012

Views: 3177

Rating:

Save

Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA

At a press conference at SABCS 2012, Dr Peter Kaufman presents data on a A phase III multicenter study of eribulin mesylate in women with previously treated metastatic breast cancer failed to meet its co-primary endpoints of improved progression-free survival and overall survival compared with capecitabine.

Read more in ecancerNews.

Related Videos

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Antibody drug conjugates coming to primetime and new agents for breast cancer

Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA

Antibody drug conjugates coming to primetime and new agents for breast cancer ( Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA )

Intervention of osteoclastogenesis that occurs in breast cancer and multiple...

Dr Gregg Fields - Florida Atlantic University, Florida, USA

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced...

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Addition of atezolizumab to chemotherapy after surgery does not improve...

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )

EBCC 2024: Addressing inequalities across Europe in access to innovation for...

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr...

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr...

Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

More from ecancer